March 07, 2025CorporateUltimaster Nagomi™ and Ultimaster™ Tansei™ are now MDR certified for patients at high bleeding risk
February 27, 2025CorporateTerumo and Daiichi Sankyo partner to support cardiovascular care in Vietnam
February 25, 2025CorporateNational Alliance of Sickle Cell Centers and Terumo Blood and Cell Technologies Working Together to Improve Outcomes for Patients with Sickle Cell DiseaseThe BET on Blood for SCD collaboration aims to improve the lives of Sickle Cell Warriors by connecting healthcare providers with education about proven treatments to help manage the disease
The Latest Materials 3rd Quarter Financial Results for FYE 3/2025 February 13, 2025 Financial Statements IFRS Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2025 (PDF 248.94 KB) Presentation Material Financial Results for the Third Quarter of Fiscal Year Ending March 31, 2025 (PDF 543.7 KB) Financial Results for the Third Quarter of Fiscal Year Ending March 31, 2025 (FY2024)(with note) (PDF 312.9 KB) Additional Information Revenue by Segment (PDF 291.85 KB) Revenue by Segment (Excel 228.14 KB) Q&A Q&A Session at the Financial Results Briefing for the Third Quarter of Fiscal Year Ending March 31, 2025 (PDF 237.28 KB) Webcast Listen to the Webcast Financial Statements /investors/library/financial-statements Presentations /investors/library/presentations Terumo Report /investors/library/annual-reports Sustainability /sustainability Corporate Governance /about/governance Consolidated Financial Statements /investors/library/financial Adobe Reader is required for viewing PDF files. Download Adobe Reader
IFRS Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2025 (PDF 248.94 KB)
Financial Results for the Third Quarter of Fiscal Year Ending March 31, 2025 (FY2024)(with note) (PDF 312.9 KB)
Q&A Session at the Financial Results Briefing for the Third Quarter of Fiscal Year Ending March 31, 2025 (PDF 237.28 KB)